| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Notice to attend the annual general meeting in Scibase Holding AB (publ) | 3 | Cision News | ||
| 07.04. | SciBase reaches milestone with over 400,000 tests sold with Nevisense | 219 | PR Newswire | STOCKHOLM, April 7, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced a significant... ► Artikel lesen | |
| 13.03. | Scibase Holding AB: Interim report | 177 | GlobeNewswire (Europe) | January 1 - December 31, 2025
The fourth quarter in figures
Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%.
The loss after tax was TSEK 25,300 (21,677).
The loss per... ► Artikel lesen | |
| 10.03. | SciBase: New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment | 396 | PR Newswire | STOCKHOLM, March 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication... ► Artikel lesen | |
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 05.03. | SCIBASE: New Publication: US clinicians' real-world Nevisense experience improves melanoma detection | 3 | Cision News | ||
| 02.03. | SciBase receives approval by FDA for extended labelling in the US | 346 | PR Newswire | STOCKHOLM, March 2, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received... ► Artikel lesen | |
| 02.03. | Scibase Holding AB: SciBase receives approval by FDA for extended labelling in the US | 249 | GlobeNewswire (Europe) | STOCKHOLM, Sweden - March 2, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval... ► Artikel lesen | |
| 19.02. | SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma | 308 | PR Newswire | STOCKHOLM, Feb. 19, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense... ► Artikel lesen | |
| 17.02. | SCIBASE: A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns | 2 | Cision News | ||
| 17.02. | Scibase Holding AB: A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns | 580 | GlobeNewswire (Europe) | STOCKHOLM, Sweden - February 17, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will... ► Artikel lesen | |
| 06.02. | SciBase: Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue | 322 | PR Newswire | STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen | |
| 27.01. | SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 | 364 | PR Newswire | STOCKHOLM, Jan. 27, 2026 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on... ► Artikel lesen | |
| 27.01. | Scibase Holding AB: SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 | 177 | GlobeNewswire (Europe) | SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on 29 December 2025 (the "Rights Issue"). The Rights Issue... ► Artikel lesen | |
| 26.01. | SciBase: Change of date for publication of the year-end report for the financial year 2025 | 301 | PR Newswire | STOCKHOLM, Jan. 26, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resolved to postpone the publication of the year-end report for... ► Artikel lesen | |
| 22.01. | Increased commitment in SciBase rights issue | 269 | PR Newswire | STOCKHOLM, Jan. 22, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces it has been informed... ► Artikel lesen | |
| 09.01. | SciBase publishes information document regarding rights issue | 439 | PR Newswire | STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue... ► Artikel lesen | |
| 09.01. | SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2 | 372 | PR Newswire | STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the repurchase offer for all warrants of series TO 2 resolved... ► Artikel lesen | |
| 06.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.01.2026 | 538 | Xetra Newsboard | Das Instrument NW1 SE0017131865 WINDON ENERGY GROUP AB EQUITY wird cum Kapitalmassnahme gehandelt am 06.01.2026 und ex Kapitalmassnahme am 07.01.2026 The instrument NW1 SE0017131865 WINDON ENERGY GROUP... ► Artikel lesen | |
| 29.12.25 | The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million | 798 | PR Newswire | STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, based on the authorization granted by the Annual General... ► Artikel lesen | |
| 11.12.25 | SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent | 375 | PR Newswire | STOCKHOLM, Dec. 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that it has been granted... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 98,55 | -0,20 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 17.04.2026 -2- | The following instruments on XETRA do have their last trading day on 17.04.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.ISIN Name US5719032022 Marriott International... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,117 | +4,48 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 54,71 | +0,24 % | If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today | ||
| PAUL HARTMANN | 210,00 | +0,48 % | Paul Hartmann: Unterschätzte Medizinaktie | Normalerweise hat die Aktie der in den Bereichen Wundversorgung sowie Inkontinenz tätigen Paul Hartmann AG alles, was es für eine knackige Investmentstory braucht. Mit Erlösen von zuletzt fast 2.450... ► Artikel lesen | |
| SYSMEX | 7,984 | +1,66 % | Sysmex Europe eröffnet offiziell seinen neuen Campus in Hamburg und setzt damit neue Maßstäbe für zukunftsorientierte Arbeitsumgebungen | Hamburg (ots) - Sysmex Europe hat offiziell seinen neuen Bürocampus in Hamburg-Alsterdorf eröffnet und damit den Umzug seines EMEA-Hauptsitzes von Norderstedt in die Stadt abgeschlossen. Rund 780 Mitarbeiter... ► Artikel lesen | |
| ADDLIFE | 14,970 | +1,91 % | AddLife AB: AddLife acquires BioSpectrum Ltd | AddLife acquires BioSpectrum Ltd, a fast-growing distributor of surgical solutions in the fields of urology, gynaecology and general surgery in the UK. The company will be included within AddLife's... ► Artikel lesen | |
| EMBECTA | 8,350 | +0,31 % | Embecta Corp.: embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited | PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("Embecta") (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has entered into a definitive agreement... ► Artikel lesen | |
| ENOVIS | 22,200 | -0,89 % | Analyst Backs Enovis On Cash Flow Turnaround | ||
| PULMONX | 1,200 | -3,23 % | Pulmonx Corporation: Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026 | ||
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle and Wellness Ltd: Revitalist Lifestyle CEO Walker, CFO Murray resign | ||
| LIFECARE ASA | 0,034 | +52,73 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| KOOTH | 1,590 | 0,00 % | Kooth reports lower revenue, earnings for 2025 | ||
| BACTIGUARD | 1,505 | +4,51 % | Bactiguard Holding AB: Bactiguard Holding AB's year-end report 2025 | A year of strategic execution concluded with a strong Q4
Fourth quarter 2025 (October - December)
Total revenue amounted to SEK 65.6 (68.3) million, a decrease of SEK 2.7 million corresponding to... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,725 | 0,00 % | Peijia Medical Announces 2025 Annual Results | SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and... ► Artikel lesen | |
| SI-BONE | 11,500 | -4,96 % | Smith & Nephew Plc: Smith+Nephew signs distribution agreement with SI-BONE | Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global... ► Artikel lesen |